{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000035","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.368603+00:00","generated_at":"2026-06-25T05:42:56.871430+00:00","sec_items":["8.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Neurocrine repurchases $31.4M of 2.25% Convertible Notes due 2024 for $41.5M","bullets":["Repurchased ~$31.4M principal of 2024 Convertible Notes for ~$41.5M including accrued interest.","Transactions entered on May 31, 2022; closing expected June 2, 2022.","Repurchases are in addition to those disclosed in May 25, 2022 Form 8-K.","Company notes repurchases could affect common stock market price."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000035","json":"https://secwatch.observer/filing/0000914475-22-000035.json","markdown":"https://secwatch.observer/filing/0000914475-22-000035.md","text":"https://secwatch.observer/filing/0000914475-22-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000035/0000914475-22-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000035/nbix-20220531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:42:56.871430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}